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Abstract
Circulating tumour cells (CTC) in patients with metastatic carcinomas are associated with poor survival and can be used to
guide therapy. Classification of CTC however remains subjective, as they are morphologically heterogeneous. We acquired
digital images, using the CellSearchTM system, from blood of 185 castration resistant prostate cancer (CRPC) patients and 68
healthy subjects to define CTC by computer algorithms. Patient survival data was used as the training parameter for the
computer to define CTC. The computer-generated CTC definition was validated on a separate CRPC dataset comprising 100
patients. The optimal definition of the computer defined CTC (aCTC) was stricter as compared to the manual CellSearch CTC
(mCTC) definition and as a consequence aCTC were less frequent. The computer-generated CTC definition resulted in
hazard ratios (HRs) of 2.8 for baseline and 3.9 for follow-up samples, which is comparable to the mCTC definition (baseline
HR 2.9, follow-up HR 4.5). Validation resulted in HRs at baseline/follow-up of 3.9/5.4 for computer and 4.8/5.8 for manual
definitions. In conclusion, we have defined and validated CTC by clinical outcome using a perfectly reproducing automated
algorithm.
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Introduction
In recent years, several studies have reported that a change in
circulating tumour cell (CTC) count could indicate whether a
therapy for advanced cancer is effective [1,2,3,4,5,6,7]. It is
envisioned that the clinical use of CTC as a pharmacodynamic
and predictive biomarker will rapidly increase in the near future,
especially in advanced prostate and breast cancers [8]. Currently,
the CellSearchTM method is the only clinically validated and FDA-
cleared method for CTC enumeration [9]. In this system, objects
that are positive for epithelial cell adhesion molecule (EpCAM)
antigen are enriched from 7.5 ml of blood and then stained with
cytokeratin-phycoerythrin (CK-PE), CD45-allophycocyanin
(CD45-APC) and the nuclear dye 4#,6-diamidino-2-phenylindole
(DAPI). The recorded fluorescence images of CK-PE, DNA-
DAPI, CD45-APC and a debris-fluorescein (FITC) channel are
segmented on the basis of being positive for CK-PE and DAPI and
are then presented to a trained reviewer for identification of CTC
that are CK-PE positive, CD45-APC negative, $4 mm in
diameter, DAPI-positive, and have a cell-like morphology. This
manual procedure is laborious, time-consuming and can be highly
subjective. For example, others have described an inter-reviewer
variation in manual CTC enumeration of 4% to 31% (median
14%) [10]. Moreover, CTC are known to be morphologically
heterogeneous and in fact, different laboratories have used
different definitions for what constitutes a CTC, especially for
objects that are dead or apoptotic [2,10]. CTC can occur at very
low frequencies and therefore misjudging a few events could be
very significant [11]. Also, the definition of what to call a CTC
that is currently used may not be optimal. A recent report showed
that tumour micro particles (TMPs) -EpCAM+CK+CD45- objects
smaller than 4 mm- are also associated with poor prognosis,
suggesting alternative definitions for CTC evaluation should be
considered [12].
Here we present the results of a new approach to identify CTC
in images captured by the system in samples from castration-
resistant prostate cancer (CRPC) patients. We recorded images
before treatment (baseline samples) and from a follow-up sample
taken 2–6 weeks after start of therapy. Our hypothesis was that
using survival data as the only training parameter, an automated
algorithm could be optimized to define and automatically count
CTC with the same fidelity as the manual CellSearch method
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(mCTC). This algorithm needs to identify automated CTC
(aCTC) candidates, characterize them and compare the candi-
dates to a range of known features. Replacement of manual CTC
counting with an automated method would significantly reduce
cost and importantly, eliminate inter- and intra-laboratory
variation that could be clinically important in cases with low
CTC counts. Moreover, a consensus definition for what constitutes
a CTC is urgently required [13]. By using an unbiased approach
to identify clinically important events, our analyses informs on the
validity of different criteria currently being used, which were
validated on an independent data set.
Methods
Ethics Statement
Development of image analysis algorithms for automated CTC
enumeration was performed on stored images from ten CellSearch
systems (Veridex LLC, Raritan, NJ) from patients participating in
the prospective IMMC-38 study (NCT00133900) and healthy
individuals participating in the IMMC-06 study (NCT00133913)
were available [7,14]. For validation of the algorithm, images were
used from samples from patients participating in Phase I and II
clinical studies of abiraterone acetate (NCT00473512) conducted at
the Royal Marsden NHS Foundation Trust and reported previously
[15,16,17]. Samples were processed at The Institute of Cancer
Research (ICR) (Sutton, UK) and archived images were sent for
automated analysis at the University of Twente (Netherlands). The
University of Twente was blinded to survival data for the validation
samples. These studies were approved by the Ethics Review
Committees of the participating centres: the United States
Institutional Review Board for IMMC-38; the United States Food
and Drug Administration and the United Kingdom Medicines and
Healthcare Products Regulatory Agency for abiraterone acetate. All
patients and healthy individuals provided written informed consent.
Participants
All patients had histologically confirmed prostate adenocarcinoma,
castrate levels of testosterone (,50 ng/ml) and progressive disease as
defined by three consecutively rising PSA values [18]. Patients
included in IMMC-38 were commencing a new cytotoxic therapy.
Patients with brain metastases or a history of other malignancies
within the last 5 years were excluded. 276 patients were enrolled in
IMMC-38, 231 met eligibility criteria and for 185 of those patients
images could be imported for baseline and first follow-up [14].
Baseline samples were taken up to 19 days prior to commencement of
a new cytotoxic chemotherapy, follow-up samples were taken 2–6
weeks after the start of therapy. 121 patients started their first line of
chemotherapy. A total of 65 clinical centres in the United States and
Europe participated in this study. In the abiraterone acetate studies,
samples were collected from a total of 100 patients. 89 patients
contributed both a baseline and a follow-up sample, 7 contributed
only follow-up, 4 only baseline. Fifty-one patients were chemotherapy
naı¨ve, and 44 patients were docetaxel-pretreated. Samples collected
up to 14 days before initiation of abiraterone acetate (93 samples) and
after one cycle (28 days) of therapy (96 samples) were used for this
analysis. Of 185 IMMC-38 patients 118 (64%) died, in the
abiraterone acetate studies 73 of 100 (73%) died. Median survival
was 20.7 months for IMMC-38 and 31.5 months for abiraterone
acetate. Median duration of follow-up for censored patients was 29.8
months for IMMC-38 and 41.8 months for abiraterone acetate. In
addition, samples of 68 healthy individuals participating in the
IMMC-06 study were available [7]. Healthy individuals donated
blood at three clinical centres in the US, the Netherlands, and the
United Kingdom.
Manual Counting of Circulating Tumour Cells (mCTC)
The CellSearch system was used to isolate and image EpCAM+
objects. The CellSearch system consists of a CellTracks Autoprep
for sample preparation [2,9] and a CellTracks Analyzer II for
sample analysis. The CellTracks Autoprep immuno-magnetically
enriches epithelial cells from 7.5 ml of blood using ferrofluids
conjugated to epithelial cell adhesion molecule antibodies
(EpCAM). The enriched sample is stained with phycoerythrin-
conjugated (PE) antibodies directed against cytokeratins 8, 18, and
19 (CK), an allophycocyanin-conjugated (APC) antibody to CD45
and the nuclear dye 4#,6-diamidino-2-phenylindole (DAPI). This
enriched sample is transferred to a magnetic cartridge where all
ferrofluid labeled objects are pulled towards an analysis surface.
The entire analysis surface is imaged by the CellTracks Analyzer
II, a four-color semi-automated fluorescence microscope that
captures digital images for four different fluorescent dyes using a
10X/0.45NA objective. In addition to the DAPI, PE and APC
images, a fourth fluorescence channel (emission 535625 nm) is
imaged as a control channel for exclusion of auto-fluorescent
debris. This channel will be termed ‘‘FITC’’ channel. Per
cartridge, a whole scan consists of 144–180 4-layer tiff images
that are saved for each patient. After imaging by the Celltracks
analyzer, the software selects objects that are DNA and CK
positive and presents them to an operator in a thumbnail gallery.
The operators are trained to reviews these galleries to select the
mCTC among the objects. An mCTC is positive for DNA and
CK, is negative for CD45, is larger than 464 mm and has
morphological features that are consistent with those of a cell.
Automated counting of EpCAM+ objects using a
computer algorithm (aCTC)
CDs containing up to 180 archived four channel tiff images for
each sample belonging to the respective studies were collected for
import to a central hard drive. Objects were detected and classified
using an automated algorithm developed in Matlab 2009a (Math-
works, Natick, MA) using the DIPimage toolbox (www.diplib.org).
An outline of the method is given below and shown in figure 1. The
method was applied for each patient sample separately. First, the true
imaging area where all the objects were located was determined via
sample cartridge edge detection in the debris-FITC channel.
Candidate CTC objects were selected via object segmentation in
the CK-PE channel. Segmentation was performed using a threshold
which was determined for each sample via the channel image
histogram [19]. Applying this threshold to the CK-PE images
returned the outline, size and location of the objects. In the next step,
measurements, termed features from here on, were performed on
these objects and the features providing the largest Cox hazard ratio
(HR, shown next to the features in figure 1) and low correlation with
other selected features were chosen for classification of these objects:
the standard deviation of the signal in the CK-PE channel, the peak
signal value in both the DNA-DAPI and CD45-APC channels and
the size of the objects. Finally, selection of aCTC was performed by
comparing every object to numerical inclusion criteria for these four
features. The combined inclusion criteria -termed classifier from here
on- were varied to find the aCTC definition that most strongly
associated with high HR for baseline and follow-up samples, a higher
HR for follow-up than baseline samples, and a low relative and
absolute count in control samples. Bootstrap aggregation was used to
test the stability of the optimal classifier [20].
Statistical analysis
The primary objective was to identify a CTC definition with the
largest HR between favourable and unfavourable patient groups
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and a low background in the control group. During algorithm
development, the median number of events found was used to
dichotomize patients into two groups. This approach allowed
quick selection of a threshold, while ensuring that sufficient
patients are present in both the ‘at risk’ and the ‘not at risk’ groups.
It also allowed comparison of HR determined for different features
and minimized error in HR. For this approach to work there
needs to be a continuous relationship between survival and CTC
count, which was previously demonstrated for the IMMC-38 data
[21].
After algorithm optimization, all patient samples were processed
by the algorithm and the training and validation patient groups
were dichotomized on cut-off values ranging 1–10 of aCTC and
mCTC to derive HR and median overall survival (OS) for baseline
and first follow-up samples. Furthermore, a linear regression was
performed for comparison between the aCTC and mCTC count.
Classifiers with reduced features were tested to determine the
impact of each feature. Pearson coefficient of determination R2
was determined between these populations using Matlab.
Statistical HR and Kaplan Meier analysis for the training dataset
was performed by S.T.L. using Matlab and GraphPad Prism v5.
Statistical HR and Kaplan Meier analysis for the validation
dataset was performed by A.M.C. at the ICR using Stata v10.1
(StataCorp) and GraphPad Prism v5.
Results
Choosing the optimal classifier and processing of
samples
The classifier resulting in the optimal aCTC definition that most
strongly associated with high HR for baseline and follow-up
samples was chosen. The features that most strongly associated
with OS were: a CK-PE standard deviation .50 counts, a size
range of 75–500 pixels (34–224 mm2), a DAPI-DNA peak value
.170 counts and a CD45-APC peak value ,60 counts. For every
patient sample, the objects meeting these inclusion criteria were
added up to arrive at a final aCTC count per patient. The mCTC
count was performed by trained reviewers. Time needed for
preparation of images for mCTC assignment was similar to the
time needed for complete aCTC enumeration; both took 5
minutes. However, enumeration of these mCTC by a human
operator takes an additional 8 minutes per sample (median 5,
range 1–39, SD 8 minutes, N = 43).
Automated CTC count compared to manual CTC count in
patients and controls
After all the objects meeting the criteria of the optimal classifier
were summed for each patient sample, the aCTC count was
compared with the mCTC count. In the baseline samples the
aCTC counts ranged from 0 to 3384 (median 5, mean 78, SD 333)
compared to mCTC counts of 0 to 5925 (median 7, mean 101, SD
497). The R2 between aCTC and mCTC was 0.80 (slope = 1.33,
intercept =23.03). In the follow-up samples aCTC counts ranged
from 0 to 870 (median 2, mean 27, SD 86) compared to mCTC
counts of 0 to 545 (median 2, mean 30, SD 87). The R2 was 0.67
(slope = 0.85, intercept = 7.18). Figure 2 shows a scatter plot of the
baseline and follow-up samples with the linear regression and
corresponding statistics of the combined baseline and follow-up
samples. In 68 control samples only one object was classified as
aCTC and zero objects as mCTC.
Figure 3 shows the frequency distributions of mCTC (median 7)
and aCTC (median 5) in baseline samples from patients and in
controls for the optimal aCTC definition and three other
definitions that are less strict: without the CD45 feature (median
Figure 1. Schematic overview of the aCTC classifier development process. A: importing of images; B: object segmentation; C: feature
measurements; D: classification of aCTC.
doi:10.1371/journal.pone.0027419.g001
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10), without the DAPI feature (median 40), and for TMP objects
that are EpCAM+CK+CD45- (CK standard value .10 counts;
CD45 peak value ,60 counts ) and ,4 mm in diameter (median
104). R2 between aCTC and mCTC was 0.78. Between aCTC
and the objects found with the classifiers without CD45 and DAPI
the R2 were 0.95 and 0.82, respectively. Between the aCTC and
TMP definition, the R2 was 0.56 (p,0.0001 for all R2).
Defining cut-off values for aCTC and mCTC
To arrive at a clinically relevant cut-off value for aCTC
comparable to the mCTC cut-off of 5 used in routine clinical
practice, we used the linear regression slope of 1.33 between
aCTC and mCTC baseline measurements. This resulted in a cut-
off of 4 aCTC. In the scatter plot of figure 2 the cut-offs are
indicated creating four quadrants: two with concordant and two
with discordant results. The percentage of patients in each
quadrant is provided. A total of 11% of patients had discordant
results based on the CTC cut-offs of mCTC and aCTC. The
influence of other CTC cut-off values from $1 to $10 CTC on
the number of patients affected, the median OS, HR and its
significance for both baseline and follow-up samples were
determined and are shown in table 1 (p-values for all
HRs,0.0001, except baseline cut-off = 1: p = 0.0003 for aCTC
and p = 0.004 for mCTC).
Kaplan-Meier plots were generated for 185 baseline and 185
follow-up samples using the standard cut-off value of 5 for mCTC
and the cut-off value for aCTC of 4. Figure 4, panel A shows the
Kaplan-Meier plot for the baseline samples. Cox regression
yielded a HR of 2.8 (95% CI 1.9–4.1) for aCTC and a HR of 2.9
(95% CI 2.0–4.4) for mCTC. Figure 4, panel B shows the Kaplan-
Meier plot for the follow-up samples. For the first follow-up
Figure 2. Scatter plot of baseline (dark grey) and first follow-up
(light grey) samples, counted by the aCTC and mCTC methods.
The linear regression statistics apply to the total data set. Quadrants
were defined by the clinically used cut-off value of 5 mCTC and the
empirical determined value of 4 aCTC (dashed lines). In each quadrant,
the percentage of patients is shown.
doi:10.1371/journal.pone.0027419.g002
Figure 3. Frequency distributions of mCTC and aCTC from patients (N=185) and control samples (N=68). The top row shows the
mCTC frequency distribution (panel A). The next rows show the number of aCTC for the optimal aCTC definition (panel B), the classifier without the
CD45 exclusion criterion (panel C), without the DAPI criterion (panel D), and of TMP objects that are EpCAM+CK+CD45- and ,4 mm in diameter
(panel E). The percentage of patients with 0 objects is shown numerically on the left. On the right the HRs derived by dichotomizing on the median
number of objects in patients are shown, together with the 25, 50, and 75 percentiles. The percentiles are also indicated in the plot.
doi:10.1371/journal.pone.0027419.g003
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samples we found a HR of 3.9 (95% CI 2.6–5.9) for aCTC and a
HR of 4.5 (95% CI 3.0–6.8) for mCTC.
Validation of automated CTC count
To validate the aCTC count an independent data set was used
from 100 metastatic prostate cancer patients treated with
abiraterone acetate. The set included 93 baseline samples 96
follow-up samples. In the baseline samples the aCTC counts
range was 0–1258 (median 3, mean 46, SD 152) and a range of
0–1108 (median 6, mean 53 SD 151) was found for mCTC. R2
between aCTC and mCTC was 0.28 (slope = 0.52, inter-
cept = 28.76). Exclusion of a single outlier resulted in a R2 of
0.90 (slope 1.72, intercept 4.07). In the follow-up samples the
aCTC counts range was 0–2490 (median 2, mean 78, SD 326)
and a range of 0–3573 (median 2, mean 74, SD 390) with
mCTC. R2 between aCTC and mCTC both was 0.83
(slope = 1.09, intercept =211.43).
Kaplan-Meier plots were generated for 93 baseline and 96
follow-up samples using the standard CTC cut-off of 5 for mCTC
and 4 for aCTC. Figure 4 Panel C shows the Kaplan-Meier plot
from the baseline samples. Cox regression resulted in a HR of 3.9
(95% CI 2.4–6.6) for aCTC and a HR of 4.8 (95% CI 2.8–8.3) for
mCTC. The Kaplan Meier plot from follow-up samples is
presented in figure 4, panel D. A HR of 5.4 (95% CI 3.2–8.9)
was found for aCTC and a HR of 5.8 (95% CI 3.4–9.8) for mCTC
(p-values for all HRs,0.0001). Table 2 shows the influence of
other cut-off values on the HR and OS.
Discussion
This is the first report of an algorithm-based automated method
for unbiased determination of a clinically significant definition for
what constitutes a CTC. We used stored images recorded by the
CellSearch system from 185 patients with metastatic CRPC.
While the algorithm was developed using patients with metastatic
CRPC receiving a cytotoxic agent (training cohort), validation on
patients receiving the highly active hormonal agent abiraterone
acetate (validation cohort) confirmed reproducibility of the
enumeration algorithm.
For the purpose of the development of the CTC classifier,
patients were divided into two groups based on the median aCTC
count in the training set of 185 baseline samples. This division was
chosen to minimize statistical error in the HR. The median count
for the chosen aCTC classifier on the baseline samples was 5
aCTC and resulted in a HR of 3.1. The current standard
CellSearch method presents the reviewer with CK+ DAPI+
objects for classification: a threshold of 5 or more mCTC is used to
discriminate between patients with a favourable versus an
unfavourable prognosis. In an earlier study we reported that this
threshold of 5 mCTC could be mainly attributed to error
introduced by human interpretation [11]. The variability of
counting aCTC by the algorithm is 0% compared to inter-
reviewer variability of 4% to 31% for mCTC (median 14%) [10].
As we have eliminated this variability by using an automated
method, one could argue that the presence of any CTC could now
be used to identify patients at risk. To identify a threshold for
Table 1. aCTC and mCTC cut-off values with HRs, median OS, for baseline (panel A) and first follow-up samples (panel B) for the
training set enrolled in the IMMC-38 study.
A (N=185) Classifier CellSearch
cut off n$cut off (%)
50% OS*
,cut off
50% OS
$cut off HR{ (95% CI) n$cut off (%)
50% OS
,cut off
50% OS
$cut off HR (95% CI)
1 147 (79) 33.0 17.5 2.6 (1.6–4.5) 145 (78) 32.0 17.4 2.0 (1.2–3.2)
2 126 (68) 33.3 15.8 3.0 (1.9–4.8) 128 (69) 33.3 15.6 2.8 (1.8–4.4)
3 115 (62) 33.3 15.2 3.0 (1.9–4.6) 118 (64) 33.1 15.2 2.9 (1.9–4.4)
4 105 (57) 33.1 14.5 2.8 (1.9–4.1) 108 (58) 32.1 14.5 2.5 (1.7–3.7)
5 93 (50) 31.2 13.6 3.1 (2.1–4.7) 104 (56) 32.0 14.5 2.9 (2.0–4.4)
6 87 (47) 32.0 12.5 3.0 (2.0–4.5) 96 (52) 32.0 13.6 2.8 (1.9–4.2)
7 82 (44) 31.0 11.5 3.2 (2.2–4.8) 95 (51) 32.0 13.6 3.1 (2.1–4.5)
8 75 (41) 30.6 11.4 3.1 (2.1–4.6) 87 (47) 31.2 11.5 3.2 (2.1–4.7)
9 72 (39) 30.6 11.4 3.0 (2.0–4.4) 84 (45) 31.2 11.4 3.4 (2.3–5.0)
10 70 (38) 29.0 11.4 2.9 (1.9–4.3) 78 (42) 30.6 10.6 3.2 (2.1–4.7)
B (N = 185)
1 129 (70) 31.4 15.2 2.3 (1.6–3.5) 110 (59) 33.4 12.5 3.0 (2.1–4.5)
2 98 (53) 29.6 11.6 3.6 (2.4–5.3) 94 (51) 31.1 11.5 3.9 (2.6–5.7)
3 79 (43) 29.6 9.8 4.0 (2.7–5.9) 81 (44) 31.2 10.3 4.4 (2.9–6.5)
4 72 (39) 29.6 9.6 3.9 (2.6–5.9) 77 (42) 31.2 10.3 3.8 (2.5–5.6)
5 67 (36) 28.3 9.5 4.8 (3.2–7.3) 71 (38) 30.6 10.5 4.5 (3.0–6.8)
6 62 (34) 28.3 9.4 4.4 (2.9–6.6) 64 (35) 29.3 10.2 4.7 (3.1–7.1)
7 57 (31) 25.7 9.4 4.4 (2.9–6.6) 62 (34) 29.3 10.2 4.5 (3.0–6.8)
8 57 (31) 25.7 9.4 4.5 (2.9–6.8) 58 (31) 28.2 9.2 4.7 (3.1–7.1)
9 53 (29) 25.7 9.4 4.0 (2.6–6.1) 55 (30) 28.2 9.2 4.7 (3.1–7.2)
10 49 (26) 25.6 9.4 3.9 (2.6–6.0) 51 (28) 27.5 9.2 4.3 (2.8–6.6)
*Overall Survival; {Hazard Ratio.
doi:10.1371/journal.pone.0027419.t001
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aCTC we used the correlation statistics between mCTC and
aCTC and proposed a cut-off for aCTC of 4. As shown in figure 4,
the Kaplan-Meier plots before and after one cycle of treatment
using aCTC and mCTC are equivalent. The aCTC classifier that
was chosen detected up to one object in the control samples as can
be seen in figure 3. From this figure it becomes clear that a CD45
exclusion criterion is necessary to suppress the number of
background objects, although the impact on the HR is small.
The influence of the DAPI exclusion criterion is large on HR: only
cells with sufficient DNA should be included.
Although one would expect that counting tumour related events
that occur at a higher frequency -such as TMPs [12]- is more
sensitive and robust, the relationship with clinical outcome was less
strong. The aCTC definition was stricter as compared to the
mCTC definition as is exemplified by the frequency differences.
R2 between TMP and aCTC was 0.56 and TMPs were also
present in the control group (see figure 3 bottom row). This may
suggest that the current definition of TMPs is a proxy for the
number of viable CTC, but in addition enumerates objects
unrelated to tumor metastasis (e.g. originating from cell death in
tumor or healthy tissue). Higher numbers of events are needed to
improve robustness. TMPs may provide these higher numbers, but
additional markers are needed to suppress the background signal
in healthy volunteers.
The aCTC definition was validated using an independent data
set. This validation set showed that the classifier performs well with
equivalent HRs to those obtained with mCTC. Correlation with
mCTC was quite low (R2 0.28) due to one outlier. For this outlier,
the algorithm counted 1258 aCTC, whereas the operator only
counted 67 mCTC. Closer inspection of this sample revealed that
this sample had a very high density of cells. This resulted in an
overestimation of the number of CTC by the algorithm and an
underestimation of the number of CTC by the human operator.
Kaplan-Meier plots of baseline and follow-up using aCTC and
mCTC from the validation set illustrated in figure 4 strongly
support the use of the aCTC for routine clinical use. Whether or
not the same definition for an aCTC can be used for other cancers
remains to be determined and is currently being investigated in a
large number of samples from breast and colorectal cancer
patients. The definition of aCTC in this study was optimized
towards the clinical outcome of the patients and developed using
stored images taken with a 10X/0.45NA objective. The imaged
objects were selected immune-magnetically targeting the EpCAM
antigen and stained with DAPI, CD45-APC, Cytokeratin 8,18 &
19-PE. Alteration of the microscope or reagents used to identify
the CTC will obliterate the aCTC definition. To use this approach
for other CTC capturing methods clinical studies will need to be
conducted and images stored for relating the particular CTC
definition to clinical outcome.
The CellSearch system is the first and currently the only
clinically validated method for CTC enumeration. The system was
introduced in 2004 and its initial users were well-trained clinical
Figure 4. Kaplan-Meier plots of the classifier (grey lines) and the manual CellSearch (black lines) definition. The training set is shown in
panel A (baseline, N= 185) and panel B (follow-up, N= 185). Kaplan-Meier plots for the validation set are shown in panel C (baseline, N= 93) and panel
D (follow-up, N= 96). Censoring is indicated by vertical marks on the Kaplan-Meier plot.
doi:10.1371/journal.pone.0027419.g004
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researchers. The need for CTC counts in the clinic to manage
patients with metastatic disease is however rising quickly and is
accompanied by a need for simplification, higher reproducibility
and a reduction of time needed to obtain a result, i.e. cost
reduction. The introduction of aCTC addresses these issues as the
need for extensively trained reviewers is eliminated, the algorithm
is perfectly reproducible and no operator time is needed to review
the images.
In conclusion, we have identified and validated a definition for
CTC using an unbiased, automated algorithm that confirms that
CK+DAPI+CD45- cells are the EpCAM positive events most
strongly associated with survival. Moreover, automated counting
of CTC using our classifier compares favourably to manual
counting using the CellSearch system.
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